Vineti Stock

vineti.comHealthcare / Healthcare softwareFounded: 2016Funding to Date: $107.72MM

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. This company was founded by Razmik Abnous, Amy DuRoss, Malek Faham, Heidi Hagen, Stephen Ting in 2016 and is headquartered in San Francisco, CA. Vineti's software solution Personalized Therapy Management (patent pending) automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations.

Register for Details

For more details on financing and valuation for Vineti, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Vineti.

Register Today

Team

Management Team

Joe DePinto
Chief Commercial Officer
Brett Robertson
Chief Financial Officer
Amy DuRoss
Co-Founder & Chief Executive Officer
Phil Calvin
Chief Technology Officer
Subbu Viswanathan
Compliance Officer & SVP, Quality, Security & Compliance
Louise Rose Pacini
Chief Operations Officer
Heidi M. Hagen
Co-Founder

Board Members

Eli Casdin
Casdin Capital
Neil Kurtz
Medidata
Michael Pellini
Section 32
John kontor
Optum
Nina Kjellson
Canaan Partners
Michele Holcomb
Cardinal Health
Emily Melton
Threshold Ventures

Other companies like Vineti in the Healthcare software sector

Sector
Last Round Est. Valuation
$656.14MM
Sector
Last Round Est. Valuation
$1.22B
Sector
Last Round Est. Valuation
$977.06MM
Sector
Last Round Est. Valuation
$6.1B
Sector
Last Round Est. Valuation
$402.35MM
Sector
Last Round Est. Valuation
$962.09MM
Sector
Last Round Est. Valuation
$742.72MM
Sector
Last Round Est. Valuation
$920.88MM

News Highlights

Vineti announces agreement with Imvax to utilize Vineti's PTM Essentials™ solution
Vineti’s enterprise technology will enable critical patient-specific Chain of Custody management for Imvax, supporting Imvax’s goal of reaching more...
Drugmakers flock to Vineti's fix for a cell, gene therapy problem
A coalition of drugmakers has agreed to work with Vineti, a San Francisco-based technology company, to usher in new standards that could ease some of the safety and logistic concerns surrounding advanced medicines like cell and gene therapies.
Vineti Extends Series C Funding Round to $68M with an Expanded Investor Coalition
This $33 million extension to Vineti’s Series C in February 2020 will be used to further grow the company’s leading enterprise platform for advanced...
Updated on: Sep 26, 2023